MA43732A - Procédé de diagnostic d'un cancer pouvant être traité par un promédicament étoposide - Google Patents

Procédé de diagnostic d'un cancer pouvant être traité par un promédicament étoposide

Info

Publication number
MA43732A
MA43732A MA043732A MA43732A MA43732A MA 43732 A MA43732 A MA 43732A MA 043732 A MA043732 A MA 043732A MA 43732 A MA43732 A MA 43732A MA 43732 A MA43732 A MA 43732A
Authority
MA
Morocco
Prior art keywords
etoposide
procedure
treatment
diagnosing cancer
cancer suitable
Prior art date
Application number
MA043732A
Other languages
English (en)
Inventor
Nalan Utku
Original Assignee
Cellact Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellact Pharma Gmbh filed Critical Cellact Pharma Gmbh
Publication of MA43732A publication Critical patent/MA43732A/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G01N2333/918—Carboxylic ester hydrolases (3.1.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
MA043732A 2016-02-24 2017-02-24 Procédé de diagnostic d'un cancer pouvant être traité par un promédicament étoposide MA43732A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16157179.9A EP3211091A1 (fr) 2016-02-24 2016-02-24 Procédé pour le diagnostic du cancer traitable par un promédicament à étoposide

Publications (1)

Publication Number Publication Date
MA43732A true MA43732A (fr) 2018-11-28

Family

ID=55436031

Family Applications (1)

Application Number Title Priority Date Filing Date
MA043732A MA43732A (fr) 2016-02-24 2017-02-24 Procédé de diagnostic d'un cancer pouvant être traité par un promédicament étoposide

Country Status (6)

Country Link
US (1) US11892454B2 (fr)
EP (2) EP3211091A1 (fr)
JP (1) JP7143217B2 (fr)
CA (1) CA3015427A1 (fr)
MA (1) MA43732A (fr)
WO (1) WO2017144648A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112888948A (zh) * 2018-08-10 2021-06-01 豪夫迈·罗氏有限公司 用于评定Afib相关性脑卒中的CES-2（羧酸酯酶-2）

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030108484A1 (en) * 2001-04-30 2003-06-12 Mcgill University Individualization of therapy with antineoplastic agents
ATE483714T1 (de) * 2001-12-03 2010-10-15 Universitaetsklinikum Charite Podophyllotoxine als antiproliferative mittel
JP5727000B2 (ja) * 2010-04-16 2015-06-03 ツェルアクト ファーマ ゲーエムベーハー 腫瘍の処置のためのエポトシドのアナログ
EP2558477B1 (fr) * 2010-04-16 2016-09-07 CellAct Pharma GmbH Analogues d'étoposide pour le traitement de tumeurs métastatiques
WO2012167255A1 (fr) * 2011-06-03 2012-12-06 The Regents Of The University Of Colorado, A Body Corporate Thérapies par promédicaments anticancéreux
GB2513299A (en) * 2013-03-12 2014-10-29 Cellact Pharma Gmbh Biomedizinzentrum Compounds for targeting cancer stem cells

Also Published As

Publication number Publication date
WO2017144648A1 (fr) 2017-08-31
US11892454B2 (en) 2024-02-06
EP3420105B1 (fr) 2024-04-17
CA3015427A1 (fr) 2017-08-31
JP7143217B2 (ja) 2022-09-28
US20190086418A1 (en) 2019-03-21
EP3420105A1 (fr) 2019-01-02
JP2019507878A (ja) 2019-03-22
EP3211091A1 (fr) 2017-08-30

Similar Documents

Publication Publication Date Title
MA42238A (fr) Procédés de diagnostic du cancer de la vessie
DK3706615T3 (da) Vaginal speculum
GB201716088D0 (en) Vehicle light Diagnostic
IL294121A (en) An RNA test to diagnose the type of infection
MA45281A (fr) Procédés de diagnostic pour thérapie par lymphocytes t
GB201719423D0 (en) Diagnostic tests
EP3494877C0 (fr) Dispositif d'examen des neurones
MA47215A (fr) Procédés prédictifs et diagnostiques pour le cancer de la prostate
FR3038827B1 (fr) Ensemble d’instrumentation chirurgicale
PL3544525T3 (pl) Narzędzie do rozciągania skóry
DE112017005876A5 (de) CVT-Antriebsstrang
DK3580567T3 (da) I vitro-fremgangsmåde til diagnose af lungkræft
DE112018003018A5 (de) Medizinisches Punktionsinstrument
MA43732A (fr) Procédé de diagnostic d'un cancer pouvant être traité par un promédicament étoposide
KR20180084983A (ko) 암의 치료를 위한 피리미도-피리미다지논의 용도
FR3033747B1 (fr) Dispositif de diagnostic
UA38745S (uk) Консоль для монітора
WO2015013233A3 (fr) Procédés et compositions pour le traitement et le diagnostic du cancer de la vessie
DK3526347T3 (da) Indolamin-2,3-dioxygenase-analyse til diagnose og prognose af prostatacancer
ES1195261Y (es) Dispositivo de guiado para puncion ecoguiada
PT3794148T (pt) Métodos de diagnóstico de aneurisma ou cancro
IT201700083887A1 (it) Dispositivo per assistenza motoria del gomito
DE112017003989A5 (de) CVT-Antriebsstrang
MA53260A (fr) Procédé de conception d'un véhicule
IT201600108831A1 (it) Metodo per l’indagine conoscitiva e di ricostruzione di aspetti emotivi di un soggetto e relativo kit diagnostico